Cognitive dysfunction in a psychotropic medication-naïve, clinical high-risk sample from the ShangHai-At-Risk-for-Psychosis (SHARP) study: Associations with clinical outcomes.


Journal

Schizophrenia research
ISSN: 1573-2509
Titre abrégé: Schizophr Res
Pays: Netherlands
ID NLM: 8804207

Informations de publication

Date de publication:
12 2020
Historique:
received: 29 02 2020
revised: 16 06 2020
accepted: 19 06 2020
pubmed: 23 7 2020
medline: 22 6 2021
entrez: 23 7 2020
Statut: ppublish

Résumé

1) to assess generalizability of neurocognitive deficits reported in previous Western clinical high-risk (CHR) for psychosis studies in a prodromal program in Shanghai, China; and 2) to investigate neurocognition in CHR subjects in relation to a broader range of clinical outcomes (e.g. remission) than presence or absence of psychosis. Baseline neurocognitive assessments of CHR (n = 217) and healthy control (HC; n = 133) subjects were compared based on 1-year follow-up clinical status using MANOVA. CHR subjects were first divided into 'converter' (CHR-C; n = 41) and 'non-converter' (CHR-NC; n = 155) to psychosis groups and compared to HC and to each other. CHR subjects were then divided into 'remission' (i.e. achieved remission; n = 102), 'symptomatic' (persistent positive symptoms in the absence of conversion; n = 37) and 'poor-outcome' (converted and symptomatic subjects who did not respond to treatment; n = 57) groups. CHR neurocognitive performance was broadly impaired compared to HC; CHR-C subjects showed lower performance in processing speed and visual learning than CHR-NC. CHRs with poor clinical outcomes showed lower performance on most MCCB tasks compared to HC, particularly in learning and processing speed, as clinical outcome worsened from remission to symptomatic to poor outcome groups. Level and pattern of baseline neurocognitive weaknesses in SHARP CHR subjects were similar to those in NAPLS-2. Outcome stratification into remission, symptomatic and poor groups was associated with increasing cognitive deficits in learning and processing speed. These findings support cross-cultural generalizability and advance understanding of CHR neurocognitive heterogeneity associated with 1-year clinical outcomes.

Identifiants

pubmed: 32694037
pii: S0920-9964(20)30370-4
doi: 10.1016/j.schres.2020.06.018
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

138-146

Subventions

Organisme : NIMH NIH HHS
ID : R21 MH093294
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH101052
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH111448
Pays : United States

Informations de copyright

Copyright © 2020. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of competing interest All authors declare that they have no actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations within three (3) years of beginning the work submitted that could inappropriately influence, or be perceived to influence, their work.

Auteurs

Huiru Cui (H)

Shanghai Key Laboratory of Psychotic Disorders, SHARP Program, Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai, China; Psychiatry Neuroimaging Laboratory, Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Anthony J Giuliano (AJ)

Worcester Recovery Center & Hospital, Massachusetts Department of Mental Health, MA, USA.

Tianhong Zhang (T)

Shanghai Key Laboratory of Psychotic Disorders, SHARP Program, Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai, China.

Lihua Xu (L)

Shanghai Key Laboratory of Psychotic Disorders, SHARP Program, Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai, China.

Yanyan Wei (Y)

Shanghai Key Laboratory of Psychotic Disorders, SHARP Program, Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai, China.

Yingying Tang (Y)

Shanghai Key Laboratory of Psychotic Disorders, SHARP Program, Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai, China.

Zhenying Qian (Z)

Shanghai Key Laboratory of Psychotic Disorders, SHARP Program, Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai, China.

Lena M Stone (LM)

McLean Hospital, Schizophrenia and Bipolar Disorder Research Program, Belmont, MA, USA.

Huijun Li (H)

Florida A&M University, Department of Psychology, Tallahassee, FL, USA.

Susan Whitfield-Gabrieli (S)

Department of Psychology, Northeastern University, Boston, MA, USA.

Margaret Niznikiewicz (M)

Department of Psychology, Northeastern University, Boston, MA, USA; Department of Psychiatry, VA Boston Healthcare System, Brockton Division, Brockton, MA, USA.

Matcheri S Keshavan (MS)

Department of Psychiatry, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

Martha E Shenton (ME)

Department of Psychiatry, VA Boston Healthcare System, Brockton Division, Brockton, MA, USA; Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Research and Development, VA Boston Healthcare System, Brockton Division, Brockton, MA, USA.

Jijun Wang (J)

Shanghai Key Laboratory of Psychotic Disorders, SHARP Program, Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai, China. Electronic address: jijunwang27@163.com.

William S Stone (WS)

Department of Psychiatry, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. Electronic address: wstone@bidmc.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH